Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib versus investigator-choice chemotherapy in recurrent clear cell carcinoma of the ovary or endometrium
ISRCTN50772895Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Apr 2015
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of nintedanib in clear cell ovarian cancer and clear cell endometrial carcinoma (CCEC) (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Progression-free survival. Started Apr 2015; status: completed.
02
Drugs
nintedanib
03
Conditions
clear cell ovarian cancerclear cell endometrial carcinoma (CCEC)
Beyond the preview
Go deeper on ISRCTN50772895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN50772895.